The Role of Immune Checkpoint Inhibitors in Treating Hematologic Malignancies
Immune checkpoint inhibitor therapy is associated with improved outcomes but it may also lead to serious adverse effects.
Leukemia
LEUKEMIA
FEATURE
LATEST NEWS
Updated Acute Promyelocytic Leukemia Treatment Guidelines From the European LeukemiaNet
An expert panel from the European LeukemiaNet discussed optimal treatment strategies for patients with acute promyelocytic leukemia.
Guideline for Classifying Emetogenicity of Chemotherapy Agents in Pediatric Patients
Researchers classified 49 single-agent and 13 multiple-agent chemotherapy regimens by severity of emetogenicity.
Glucagon-Like Peptide-1 May Predict Inflammation in High-Dose Chemotherapy With Autologous Stem Cell Transplantation
Researchers measured levels of glucagon-like peptide-1 and C-reactive protein to determine their value as predictive biomarkers of toxicity.
Long-Term Outcomes of Anti-T-Lymphocyte Globulin Added to Graft-Versus-Host Disease Prophylaxis
GVHD prophylaxis including anti-T-lymphocyte globulin was associated with improved survival and quality of life.
Deferasirox May Improve Survival Outcomes in Patients With Acute Myeloid Leukemia
Additionally, hyperferritinemia both before and after transplant was found to have negative prognostic value.
Pediatric Treatment Regimens for Older Adolescents and Young Adults With Acute Lymphoblastic Leukemia
According to a study published in Blood, using a pediatric regimen for patients up to 40 years of age with acute lymphoblastic leukemia (ALL) may improve survival rates compared with historical controls. The prospective study (CALGB 10403; ClinicalTrials.gov Identifier: NCT00558519) took place from 2007 to 2012 and used the same treatment doses and schedule as…
Comparing Decitabine Administration Schedules for the Treatment of Acute Myeloid Leukemia
Safety and efficacy did not differ significantly between 2 decitabine treatment schedules for acute myeloid leukemia.
Azacitidine Maintenance May Improve Disease-Free Survival in Newly Diagnosed Acute Myeloid Leukemia
Over half of patients receiving azacitidine maintenance achieved protocol completion, supporting the feasibility of this therapeutic approach.
New B Progenitor Acute Lymphoblastic Leukemia Subtypes Identified
The identification of 8 new subtypes of B progenitor acute lymphoblastic leukemia may guide the diagnosis and development of more effective targeted therapies.
Immunobiological Features of B Cell Acute Lymphoblastic Leukemia in Adults
Researchers found some immunobiological profiles specific to patients with acute lymphoblastic leukemia.
Chemotherapy Intensification May Not Improve Outcomes in Patients With B Cell Acute Lymphoblastic Leukemia
Researchers assessed the influence of cyclophosphamide plus etoposide on disease-free survival in patients with B-cell acute lymphoblastic leukemia.
Exploring the Prognostic Value of Minimal Residual Disease From Peripheral Blood in Pediatric ALL
Minimal residual disease from peripheral blood, which is easier to obtain than bone marrow, was found to correlate with some clinical outcomes.
Risk Factors for Chemotherapy-Induced Nausea in Pediatric Patients
Nonwhite race, poor acute phase nausea control, and treatment with cisplatin were all associated with higher self-reported nausea severity scores.
Ponatinib as a Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Patients receiving ponatinib in combination with other therapeutic agents appeared to achieve sustained responses and long-term remission.
Two Mutations Prognostic of Survival in Acute Myeloid Leukemia Regardless of Hematopoietic Stem Cell Transplantation
Internal tandem duplications in FLT3 and mutations in CEBPA were independently prognostic of overall survival in patients with acute myeloid leukemia.
Outcomes of Induction Chemotherapy for Acute Myeloid Leukemia With Multilineage Dysplasia
Results of a study on the influence of induction chemotherapy on transplant outcomes for patients with acute myeloid leukemia.
Efficacy of Ibrutinib, Rituximab, and Bendamustine in Untreated CLL
Results of a phase 3 trial of efficacy that used progression-free survival as its primary endpoint.
Assessing Measurable Residual Disease in Patients With Acute Lymphoblastic Leukemia
Measurable residual disease status can inform treatment for patients with ALL, but the optimal methods for assessment and interpretation are unclear.
Azacitidine May Prevent Relapse in Patients With Measurable Residual Disease
Researchers evaluated the proportion of patients who had not experienced relapse at 6 months after initiation of azacitidine treatment.
Induction Chemotherapy Is Well Tolerated in Elderly Patients With Acute Myeloid Leukemia
The researchers reported more than 75% of patients achieved complete response after 1 cycle of the intensive chemotherapy regimen.
Unrelated Cord Blood Transplant Effectively Treats Leukemic Disease
The overall survival probability for patients with leukemic disease was not influenced by their pretransplant levels of minimal residual disease.
Phase 2 Trial of 3 Novel Regimens for Relapsed/Refractory Acute Myeloid Leukemia
A combination of alvocidib, cytarabine, and mitoxantron was found to outperform other novel treatments for relapsed/refractory acute myeloid leukemia.
Bone Marrow Core Biopsy May Be Beneficial in Workup for Chronic Myeloid Leukemia
Researchers retrospectively analyzed data from 508 patients with chronic myeloid leukemia who had received bone marrow aspiration or core biopsy.
Participation in Clinical Studies May Be Linked to Higher Remission Rates
Complete remission rates were higher for newly diagnosed patients on study compared with newly diagnosed patients off study.
Inotuzumab Ozogamicin May Be Efficacious and Safe in Relapsed Pediatric Acute Lymphoblastic Leukemia
The efficacy of inotuzumab ozogamicin in pediatric patients is less understood than in adult patients.
Relapse in Acute Myeloid Leukemia and Dysregulation of Immune Genetic Pathways
One of the effects of immune pathway dysregulation was decreased antigen presentation by MHC Class II genes.
The Price Is Right for CAR-T in Pediatric Patients, Analysis Concludes
For children with relapsed or refractory B-cell acute lymphoblastic leukemia, tisagenlecleucel was deemed cost-effective, yet long-term outcomes are still uncertain.
Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML
For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.
Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.
Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function
Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.
Harnessing the Power of Both Alemtuzumab and Rituximab in a Bispecific Antibody
Researchers hypothesized that a combination bispecific mAb in B-cell malignancies could offer a treatment option superior to existing monospecific mAbs.
Individualized Lenalidomide Plus Chlorambucil and Rituximab May Be Feasible in Advanced CLL
The feasibility of lenalidomide in combination therapy for chronic lymphocytic leukemia is in question.
Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical Trials
The RESONATE-2 trial excluded certain patients with chronic lymphocytic leukemia, leaving the efficacy and tolerability of ibrutinib in this population unknown.
Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL
Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.
Bendamustine Plus Obinutuzumab, Venetoclax Shows Therapeutic Potential in CLL
Findings in an ongoing phase 2 trial demonstrate that a sequential regimen of these agents has significant potential to improve depth of response and outcomes for patients with chronic lymphocytic leukemia.
Albumin-to-Fibrinogen Ratio May Predict Poor Outcomes in Chronic Lymphocytic Leukemia
Albumin-to-fibrinogen ratio may predict poor outcomes in patients with previously untreated chronic lymphocytic leukemia.
Ibrutinib in Chronic Lymphocytic Leukemia Deemed Not Cost-Effective by ICER Standards
No direct comparison between ibrutinib and chemoimmunotherapy as a first-line treatment exists.
In Search of the Right Sequence for Venetoclax in CLL
Researchers reveal the results of the phase 2 CLL2-BAG trial, which evaluated sequential bendamustine followed by obinutuzumab and venetoclax in patients with CLL.
Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia
A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.
8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
In an open-label study, researchers sought to determine the optimal amount of bed rest after intrathecal chemotherapy for patients with hematologic cancers.
Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia
A population study of a PETALE cohort demonstrated an association between functional health domains and psychological risk in adolescent and adult survivors of cALL.
Time of Response to TKI Therapies May Influence Patient Outcomes in CML
Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.
Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML
There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.
FDA Assigns a Breakthrough Therapy Designation to Quizartinib for Relapsed/Refractory FLT3-ITD AML
Quizartinib — an investigational FLT3 inhibitor — is the first agent in its class to demonstrate improved overall survival.
Lorazepam Did Not Improve CINV in Pediatric Acute Lymphoblastic Leukemia
A retrospective chart review was conducted to determine if adding lorazepam to granisetron would improve CINV prevention in pediatric patients with newly diagnosed ALL.
Predictors of CAR-T-Associated Neurotoxicity in B-Cell Acute Lymphoblastic Leukemia
High levels of CAR-T cell expansion in vivo and high pretreatment disease burden appeared to increase the likelihood that a neurotoxic event may occur following CAR-T administration.
FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Ivosidenib is the first-in-class FDA approval for IDH1 mutation-harboring acute myeloid leukemia.
Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
Clinical stage determined by the Binet staging system could be an accurate response surrogate among patients with chronic lymphocytic leukemia.
2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML
For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.
Researchers Pinpoint Factors Associated With the Development of Acute Myeloid Leukemia
Individuals at high risk of developing AML can be identified years before symptoms appear, a new study reports.
Want to read more?
Please login or register first to view this content.
Next post in Leukemia
